Keros Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Keros Therapeutics, Inc. (KROS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.38M, a 37.05% decline year-over-year.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.20M, a 30.06% decline year-over-year.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.99M, a 54.79% decline year-over-year.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $8.54M, a 2.77% decline year-over-year.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $28.70M, a 17.71% decline from fiscal 2024.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $34.87M, a 21.24% increase from fiscal 2023.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $28.76M, a 53.96% increase from fiscal 2022.
- Keros Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.68M, a 59.38% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.38M 10-Q · filed 2026-08-03 | $11.58M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $6.20M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $28.70M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $3.99M 10-Q · filed 2025-11-05 | $12.53M derived: sum of 2 quarters · filed 2026-08-03 | $21.39M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | $8.54M 10-Q · filed 2026-08-03 | $17.41M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $8.86M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $34.87M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $8.82M 10-Q · filed 2025-11-05 | $17.60M derived: sum of 2 quarters · filed 2025-11-05 | $25.67M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $8.79M 10-Q · filed 2025-11-05 | $16.86M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $8.07M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $28.76M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $8.71M 10-Q · filed 2024-11-06 | $15.75M derived: sum of 2 quarters · filed 2024-11-06 | $21.44M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $7.04M 10-Q · filed 2024-11-06 | $12.73M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $5.69M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $18.68M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $4.75M 10-Q · filed 2023-11-06 | $9.55M derived: sum of 2 quarters · filed 2023-11-06 | $13.94M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $4.79M 10-Q · filed 2023-11-06 | $9.18M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $4.39M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $11.72M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $3.08M 10-Q · filed 2022-11-03 | $5.93M derived: sum of 2 quarters · filed 2022-11-03 | $8.43M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $2.85M 10-Q · filed 2022-11-03 | $5.34M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $2.49M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $4.10M 10-K · filed 2022-03-09 | |||
| 2020-09-30 | $1.42M 10-Q · filed 2021-11-04 | $2.56M derived: sum of 2 quarters · filed 2021-11-04 | $2.58M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.14M 10-Q · filed 2021-11-04 | $1.15M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $12.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $59.00K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $17.00K 10-Q · filed 2020-11-10 | $30.00K derived: sum of 2 quarters · filed 2020-11-10 | $41.00K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $13.00K 10-Q · filed 2020-11-10 | $24.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $11.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |